SuperworthTG Therapeutics EPS TGTX
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $2.74
- Latest quarter, Q2 FY26
- $0.05
- −71% on a year earlier
- Fiscal year 2025
- $2.77
- +1879% on the year before
TG Therapeutics' earnings per share was $2.74 over the twelve months to Jun 30, 2026, up 641% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.05, down 71% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.77 | +1879% |
| FY2024 | $0.14 | +1300% |
| FY2023 | $0.01 | n/a |
| FY2022 | −$1.46 | n/a |
| FY2021 | −$2.63 | n/a |
| FY2020 | −$2.39 | n/a |
| FY2019 | −$1.95 | n/a |
| FY2018 | −$1.11 | n/a |
| FY2017 | −$1.91 | n/a |
| FY2016 | −$1.59 | n/a |
| FY2015 | −$1.38 | n/a |
| FY2014 | −$1.60 | n/a |
| FY2013 | −$0.81 | n/a |
| FY2012 | −$2.53 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.05 | −71% | $2.74 | |
| Q1 FY26 | $0.12 | +300% | $2.86 | |
| Q4 FY25 | $0.14 | −7% | $2.77 | |
| Q3 FY25 | $2.43 | +12050% | $2.78 | |
| Q2 FY25 | $0.17 | +325% | $0.37 | |
| Q1 FY25 | $0.03 | n/a | $0.24 | |
| Q4 FY24 | $0.15 | n/a | $0.14 | |
| Q3 FY24 | $0.02 | −97% | −$0.11 | |
| Q2 FY24 | $0.04 | n/a | $0.60 | |
| Q1 FY24 | −$0.07 | n/a | $0.22 | |
| Q4 FY23 | −$0.10 | n/a | $0.01 | |
| Q3 FY23 | $0.73 | n/a | −$0.28 |
Against its peers
Companies in Drug Manufacturers - General nearest TG Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TGTXTG Therapeutics | $2.74 | +641% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| JAZZJazz Pharmaceuticals | $14.62 | |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $0.73 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on TG Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.